PV QA 2 - Poster Viewing Q&A 2
MO_41_2553 - Curability of Radiotherapy in Elderly Patients With Early-stage Extranodal Nasal-type NK/T-cell Lymphoma: A Multicenter Study from the China Lymphoma Collaborative Group (CLCG)
Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3
Curability of Radiotherapy in Elderly Patients With Early-stage Extranodal Nasal-type NK/T-cell Lymphoma: A Multicenter Study from the China Lymphoma Collaborative Group (CLCG)
B. Chen1, S. Y. Zhu2, M. Shi3, H. Su4, Y. Wang5, X. He6, X. Li-ming7, Z. Y. Yuan7, L. L. Zhang8, G. Wu8, B. Qu9, L. T. Qian10, H. Xiaorong11, F. Q. Zhang11, Y. Zhang12, Y. Zhu13, J. Cao14, S. M. Lan14, J. X. Wu15, T. Wu16, S. Qi1, Y. Yang1, X. Liu17, and Y. X. Li1; 1State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China, 2Department of Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, 3Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, China, 4Department of Oncology, 307 Hospital, Academy of Military Medical Science, Beijing, P. R. China, Beijing, China, 5Department of Radiation Oncology, Chongqing Cancer Hospital & Cancer Institute, Chongqing, China, 6Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China, 7Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin, China, 8Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 9Department of Radiation Oncology, The General Hospital of Chinese People's Liberation Army, Beijing, China, 10Department of Radiation Oncology, The Affiliated Provincial Hospital of Anhui Medical University, Hefei, China, 11Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China, 12Department of Radiation Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, 13Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China, 14Department of Radiation Oncology, Shanxi Cancer Hospital and the Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan, China, 15Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China, 16Department of Lymphoma, Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, China, 17National Cancer Canter/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
The purpose of the present study was to determine the curability of radiotherapy and potential benefit of a new chemotherapy regimen in elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma (NKTCL).
In a multicenter study, 321 elderly patients (age > 60 years) with early-stage NKTCL were reviewed retrospectively. Patients received radiotherapy alone (n = 87), chemotherapy alone (n = 59), or combined modality therapy (CMT, n = 175). Patients were classified into groups of either low- or high-risk using four prognostic factors. Observed survival in the study cohort versus expected survival in the age- and sex- matched general Chinese population was plotted by using a conditional approach and compared by standardized mortality ratio (SMR).
Radiotherapy achieved a favorable prognosis in elderly early-stage patients and significantly improved prognosis compared with chemotherapy alone. The 5-year overall survival (OS) and progression-free survival (PFS) were 61.2% and 56.4% for radiotherapy compared with 44.7% and 38.3% for chemotherapy alone (P
< 0.001). Low-risk patients showed significantly improved survival compared with high-risk patients. Patients treated with a new CMT regimen demonstrated a significantly improved PFS compared with the old CMT regimen (71.2% vs. 44.2%, respectively, P
= 0.017). Low-risk patients following radiotherapy (SMR, 0.703; P
= 0.203) and high-risk patients that achieved PFS at 24 months (SMR, 1.490; P
= 0.111) after radiotherapy showed survival equivalent to the general Chinese population.
Our findings highlight the curability of radiotherapy and provide a risk-adapted follow-up and counsel system for elderly early-stage patients.
Author Disclosure: B. Chen: None. S. Zhu: None. H. Su: None. X. Li-ming: None. L. Zhang: None. H. Xiaorong: None. Y. Li: Employee; Cancer Hospital & Institute, CAMS & PUMC. Chairman, Department of Nuclear Medicine; Cancer Hospital & Institute, CAMS & PUMC. Chairman, Department of Radiation Oncology; Cancer Hospital & Institute, CAMS & PUMC.